Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6530
    +0.0030 (+0.47%)
     

  • OIL

    82.96
    +0.15 (+0.18%)
     

  • GOLD

    2,339.00
    +0.60 (+0.03%)
     

  • Bitcoin AUD

    98,043.34
    -3,707.05 (-3.64%)
     

  • CMC Crypto 200

    1,358.66
    -23.91 (-1.73%)
     

  • AUD/EUR

    0.6087
    +0.0016 (+0.27%)
     

  • AUD/NZD

    1.0951
    +0.0009 (+0.08%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,096.24
    +55.86 (+0.69%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,997.63
    -91.07 (-0.50%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Orion Corporation: Managers’ transactions – Jari Karlson

Orion Oyj
·1-min read

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2021 at 9.00 EET

Orion Corporation: Managers’ transactions – Jari Karlson

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

____________________________________________

Person subject to the notification requirement
Name: Karlson, Jari
Position: Chief Financial Officer
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745

Notification type: INITIAL NOTIFICATION
Reference number: 74370029VAHCXDR7B745_20210226105136_2
____________________________________________

ADVERTISEMENT

Transaction date: 2021-03-01
Venue not applicable
Instrument type: SHARE
ISIN: FI0009014377
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION

Transaction details
(1): Volume: 5,243 Unit price: 0.00000 EUR

Aggregated transactions
(1): Volume: 5,243 Volume weighted average price: 0.00000 EUR

Orion Corporation

Timo Lappalainen
President and CEO

Olli Huotari
SVP, Corporate Functions

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.